Duvelisib
Copiktra · PI3Kδ/γ inhibitor
Colitis and diarrhea → prerenal AKI.
Zydelig · IDE
PI3Kδ inhibitor · approved 2014 · 6 citations · FAERS AKI reporting ROR 1.87 (95% CI 1.57–2.24, 124 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
First-in-class PI3K-delta inhibitor whose immune-mediated colitis and severe diarrhea can dehydrate patients into prerenal AKI.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Severe immune-mediated diarrhea/colitis occurs in roughly 14-20% (grade 3+) and transaminitis is common; secondary prerenal AKI from volume loss is not separately quantified. Direct renal lesions are rare.Source: Furman et al., N Engl J Med 2014 (PMID 24450857; registrational idelalisib + rituximab CLL trial); Lampson et al., Blood Adv 2019 (PMID 30967392; grade >=3 colitis/diarrhea 15%, first-line); Coutré et al., Leuk Lymphoma 2015 (PMID 25726955; expert-panel review of idelalisib diarrhea/colitis)
Diarrhea/colitis is often delayed to a median of several months into therapy, while transaminitis tends to appear earlier, in the first weeks. Prose gives no concrete day counts.
Distilled from: “Diarrhea/colitis often delayed — a median of several months into therapy; transaminitis is typically earlier (first weeks).”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Immune-mediated inflammation of the renal interstitium — the signature kidney injury of checkpoint inhibitors.
Oral selective inhibitor of the p110-delta isoform of PI3K, which is expressed predominantly in leukocytes. Blocking PI3K-delta disrupts B-cell receptor signaling and survival in chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma.
Vasculature / Endothelium
Glomerular & peritubular capillaries
Interstitium
Supporting tissue around the tubules
6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .
Boxed warning
WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, INFECTIONS, and INTESTINAL PERFORATION Fatal and/or serious hepatotoxicity occurred in 16% of Zydelig-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue Zydelig as recommended [see Dosage and Administration (2.2) , Warnings and Precautions (5.1) ] . Fatal and/or serious and severe diarrhea or colitis occurred in 20% of Zydelig-treated patients. Monitor for the development of severe diarrhea or colitis. Interrupt and then reduce or discontinue Zydelig as recommended [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) ] . Fatal and/or serious pneumonitis occurred in 4% of Zydelig-treated patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt or discontinue Zydelig as recommended [see Dosage and Administration (2.2) , Warnings and Precautions (5.3) ] . Fatal and/or serious infections occurred in 48% of Zydelig-treated patients. Monitor for signs and symptoms of infection. Interrupt Zydelig if infection is suspected [see Dosage and Administration (2.2) , Warnings and Precautions (5.4) ]. Fatal and serious intestinal perforation can occur in Zydelig-treated patients across clinical trials. Discontinue Zydelig for intestinal perforation [see Warnings and Precautions (5.5) ] .…
Kidney rows of the label's dosage tables
From the Zydelig label (Sep 2026) · DailyMed
No row of this label's dosage table names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 7,144 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
1,622 of 7,144 reports
Reported with hospitalization
3,081 of 7,144 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 261 of the 7,144 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Idelalisib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Copiktra · PI3Kδ/γ inhibitor
Colitis and diarrhea → prerenal AKI.
Trodelvy · Antibody-drug conjugate (Trop-2/SN-38)
Diarrhea-driven prerenal AKI; emerging direct signals.
Empliciti · Anti-SLAMF7 mAb
Kidney-neutral antibody; unchanged PK in severe impairment and dialysis; no renal dose adjustment.
Xofigo · Radiopharmaceutical (alpha-emitter)
Bone-seeking alpha emitter; minimal direct renal toxicity.
Turalio · CSF1R inhibitor
Boxed hepatotoxicity; secondary renal effects.
Tivdak · Antibody-drug conjugate (tissue factor/MMAE)
Ocular/bleeding toxicity dominates; renal involvement essentially unreported.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.